Search results for "RESPIRATORY SYSTEM"

showing 10 items of 1829 documents

Morphogenetic (Mucin Expression) as Well as Potential Anti-Corona Viral Activity of the Marine Secondary Metabolite Polyphosphate on A549 Cells

2020

The mucus layer of the nasopharynx and bronchial epithelium has a barrier function against inhaled pathogens such as the coronavirus SARS-CoV-2. We recently found that inorganic polyphosphate (polyP), a physiological, metabolic energy (ATP)-providing polymer released from blood platelets, blocks the binding of the receptor binding domain (RBD) to the cellular ACE2 receptor in vitro. PolyP is a marine natural product and is abundantly present in marine bacteria. Now, we have approached the in vivo situation by studying the effect of polyP on the human alveolar basal epithelial A549 cells in a mucus-like mucin environment. These cells express mucins as well as the ectoenzymes alkaline phospha…

Aquatic OrganismsSecondary MetabolismVirus AttachmentPharmaceutical ScienceAdenylate kinaseRespiratory MucosaMucin 5ACdigestive systemArticle03 medical and health sciences0302 clinical medicinemucinPolyphosphatesDrug Discoveryotorhinolaryngologic diseasesExtracellularHumansReceptorlcsh:QH301-705.5neoplasmsinnate immunityPharmacology Toxicology and Pharmaceutics (miscellaneous)MUC1030304 developmental biologyA549 cellBiological Products0303 health sciencesBacteriaSARS-CoV-2ChemistryCell growthMucin-1MucinCOVID-19polyphosphaterespiratory systemImmunity Innatedigestive system diseasesSARS-CoV-2 spike proteinADKCell biologyATPlcsh:Biology (General)A549 Cells030220 oncology & carcinogenesishydrogelhuman alveolar cellsMarine Drugs
researchProduct

The Arg/Arg polymorphism of the ADRB2 is associated with the severity of allergic asthma

2016

ArginineGenotypeGlycineAdrenergicSettore MED/10 - Malattie Dell'Apparato RespiratorioArginine03 medical and health sciences0302 clinical medicineGenotypemedicineImmunology and AllergyHumans030212 general & internal medicineReceptorAdrenergic beta-2 Receptor AgonistsAsthmaPolymorphism Geneticbusiness.industryHomozygoteAllergic asthmaasthmamedicine.disease030228 respiratory systemImmunologyReceptors Adrenergic beta-2business
researchProduct

The AVL-mode: a safe closed loop algorithm for ventilation during total intravenous anesthesia.

1994

The Adaptive Lung Ventilation Controller (ALV-Controller) represents a new approach to closed loop control of ventilation. It is based on a pressure controlled ventilation mode. Adaptive lung ventilation signifies automatic breath by breath adaptation of breathing patterns to the lung mechanics of an individual patient. The specific goals are to minimize work of breathing, to maintain a preset alveolar ventilation and to prevent the occurrence of intrinsic PEEP. We ventilated 5 patients undergoing major abdominal procedures using ALV. ALV was tolerated well in all patients. Alveolar ventilation was preset between 5500 and 6500 ml/min. Serial dead space (Vds) and respiratory time constant (r…

Artificial ventilationAdultRespiratory ratemedicine.medical_treatmentMedicine (miscellaneous)Critical Care and Intensive Care MedicinePositive-Pressure Respiration IntrinsicWork of breathingBreathing patternControl theoryMedicineHumansAgedVentilators MechanicalTotal intravenous anesthesiabusiness.industryLung mechanicsdigestive oral and skin physiologyrespiratory systemRespiration Artificialrespiratory tract diseasesRespiratory Function TestsAnesthesiaBreathingAnesthesia IntravenousRespiratory MechanicsbusinessAlgorithmsInternational journal of clinical monitoring and computing
researchProduct

Adaptive Lung Ventilation (ALV) Evaluierung eines neuen closed loop-gesteuerten Beatmungsalgorithmus bei Eingriffen in �berstreckter Seitenlage

1996

The lateral decubitus position is the standard position for nephrectomies. There is a lack of data about the effects of this extreme position upon respiratory mechanics and gas exchange. In 20 patients undergoing surgery in the nephrectomy position, we compared a new closed-loop-controlled ventilation algorithm, adaptive lung ventilation (ALV), which adapts the breathing pattern automatically, to the respiratory mechanics with conventionally controlled mandatory ventilation (CMV). The aims of our study were (1) to describe positioning effects on respiratory mechanics and gas exchange, (2) to compare ventilatory parameters selected by the ALV controller with traditional settings of CMV, and …

Artificial ventilationSupine positionRespiratory ratebusiness.industrymedicine.medical_treatmentGeneral MedicineRespiratory physiologymedicine.diseaseAnesthesiology and Pain MedicinemedicineBreathingRestrictive lung diseaseRespiratory systembusinessAlgorithmTidal volumeDer Anaesthesist
researchProduct

Minimal clinically important difference for asthma endpoints: an expert consensus report

2020

Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a change in the patient's medical management.The aim of the current expert consensus report is to provide a “state-of-the-art” review of the currently available literature evidence about MCID for end-points to monitor asthma control, in order to facilitate optimal disease management and identify unmet needs in the field to guide future research.A series of MCID cut-offs are currently available in literature and validated among populations of asthmatic patients, with most of the evidence focusing on outcomes as patient repo…

Asthma asthma management minimal clinically important difference end-pointsPulmonary and Respiratory Medicinemedicine.medical_specialtyConsensusDelphi TechniqueEndpoint DeterminationBronchoconstrictionMEDLINEDelphi methodSocio-culturaleSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOminimal clinically important difference; asthma; lung function; biomarkersMCID03 medical and health sciences0302 clinical medicinePredictive Value of TestsmedicineHumansAnti-Asthmatic Agents030212 general & internal medicineDisease management (health)Intensive care medicineLungAsthmalcsh:RC705-779business.industryMinimal clinically important differenceminimal clinically important differenceExpert consensusend-pointslcsh:Diseases of the respiratory systemmedicine.diseaseMCID asthmaAsthmaTreatment Outcome030228 respiratory systemPredictive value of testsEndpoint DeterminationInflammation MediatorsSymptom AssessmentbusinessBiomarkersasthma managementEuropean Respiratory Review
researchProduct

"Table 29" of "Properties of hadronic Z decays and test of QCD generators"

1992

N-jet production rates (in percent) corrected for charged and neutral particles.

Astrophysics::High Energy Astrophysical PhenomenaE+ E- --> HADRONSE+ E- --> Z0Integrated Cross Section91.2Jet Productionrespiratory systemCross Sectionequipment and suppliesSIGcomplex mixturesDijet ProductionE+ E- ScatteringExclusiveHigh Energy Physics::ExperimentE+ E- --> 2JETR measurementhuman activitiescirculatory and respiratory physiology
researchProduct

"Table 25" of "Properties of hadronic Z decays and test of QCD generators"

1992

N-jet production rates (in percent) corrected for charged particles only.

Astrophysics::High Energy Astrophysical PhenomenaE+ E- --> HADRONSE+ E- --> Z0Integrated Cross Section91.2Jet Productionrespiratory systemCross Sectionequipment and suppliesSIGcomplex mixturesDijet ProductionE+ E- ScatteringExclusiveHigh Energy Physics::ExperimentE+ E- --> 2JETR measurementhuman activitiescirculatory and respiratory physiology
researchProduct

"Table 26" of "Properties of hadronic Z decays and test of QCD generators"

1992

N-jet production rates (in percent) corrected for charged particles only.

Astrophysics::High Energy Astrophysical PhenomenaE+ E- --> HADRONSE+ E- --> Z0Integrated Cross Section91.2Jet Productionrespiratory systemCross Sectionequipment and suppliesSIGcomplex mixturesE+ E- --> 3JETE+ E- ScatteringExclusiveHigh Energy Physics::ExperimentR measurementhuman activitiescirculatory and respiratory physiology
researchProduct

"Table 30" of "Properties of hadronic Z decays and test of QCD generators"

1992

N-jet production rates (in percent) corrected for charged and neutral particles.

Astrophysics::High Energy Astrophysical PhenomenaE+ E- --> HADRONSE+ E- --> Z0Integrated Cross Section91.2Jet Productionrespiratory systemCross Sectionequipment and suppliesSIGcomplex mixturesE+ E- --> 3JETE+ E- ScatteringExclusiveHigh Energy Physics::ExperimentR measurementhuman activitiescirculatory and respiratory physiology
researchProduct

"Table 31" of "Properties of hadronic Z decays and test of QCD generators"

1992

N-jet production rates (in percent) corrected for charged and neutral particles.

Astrophysics::High Energy Astrophysical PhenomenaE+ E- --> HADRONSE+ E- --> Z0Integrated Cross Section91.2Jet Productionrespiratory systemCross Sectionequipment and suppliesSIGcomplex mixturesE+ E- --> 4JETE+ E- ScatteringExclusiveHigh Energy Physics::ExperimentR measurementhuman activitiescirculatory and respiratory physiology
researchProduct